Defense & Real Estate Momentum Offset Textile Caution; Watch Margin Discipline
RAYMOND reports Q1 FY27 results on August 7 with a business portfolio now clearly restructured around growth vectors. The new defense CEO, a ₹331 Cr capital raise for M&A, and strong real estate pre-sales signal strategic intent—but FII outflows (down 4pp YoY) and textile pricing pressure invite caution on consolidated margins.
The Setup: Three-Vector Growth Play
RAYMOND now operates as a diversified conglomerate with three distinct growth vectors: the core textile-apparel business (premiumization underway), a newly resourced defense operation (CEO hired from BEL with 4 decades of sector depth), and Raymond Realty (pre-sales surged 129% YoY in Q1 FY27). The holding company's Q1 FY27 consolidated print will reveal how well these vectors align operationally and what top-line scale they're generating. The real story is capital allocation: ₹331 Cr raised (75% earmarked for aerospace, automotive, defense M&A) signals management intends to scale the higher-margin, higher-multiple defense/realty story—but execution risk is real.
What to Expect: Balancing Growth Investments & Margin Discipline
~₹350–380 Cr
textile softness offset by realty upside; defense still scaling
~9–10%
pressure from one-time M&A setup costs; higher-margin defense/realty to follow
elevated
warrant raise at ₹497/share signals confidence in runway; M&A pipeline active
unverified
board to approve Aug 7; prior FY26 performance suggests mid-to-high single-digit growth
A strong print would see revenue in-line or above the ₹350 Cr band with EBITDA margin holding above 9.5%, realty pre-sales momentum validated, and management commentary on defense ramp (customer traction, order pipeline). A weak print would show consolidated revenue miss, margin compression below 9%, delays in defense build-out, or realty order book slowdown. The swing factor is textile: domestic brand pricing power (premiumization narrative) vs. wholesale/garmenting volume under tariff tailwinds.
On Track? Yes—But Execution Matters
RAYMOND's prior trajectory was a modest 4–6% revenue grower with steady-state margins. The defense pivot and capital raise suggest management is betting on a faster, higher-return growth phase. The July 6 appointment of Bhanu Prakash Srivastava (former BEL CMD) as defense CEO signals serious commitment—Srivastava has 40+ years in aerospace/defense and brings credibility the business lacked. Promoter conviction is clear: JK Investors' ₹331 Cr warrant purchase at ₹497/share (upfront + 18-month exercise window) places skin in the game. What's less clear: how quickly can defense scale? Realty's 129% pre-sales pop is encouraging, but is it sustainable post-Q1? Textile domestic premiumization is real, but garmenting order tailwinds (US tariff reprieve, UK FTA) are cyclical. On plan means mid-teens to 20%+ CAGR on the defense/realty piece; anything less is a mark-miss.
What the Street Says
Since Last Quarter: Strategic & Corporate Moves
1 · Defense CEO: Bhanu Prakash Srivastava appointed Chief Executive Officer – Defence (Jul 6)
Former CMD of Bharat Electronics Limited; 40+ years in aerospace, defense electronics, manufacturing. Brings BEL's operational rigor to RAYMOND's nascent defense business. Stock responded +3.6% on announcement.
2 · Capital Raise: ₹331 Cr warrant issuance to JK Investors allotted (Jul 9)
66.57 lakh convertible warrants at ₹497/share; 75% allocated for M&A in aerospace, automotive, defense; 25% for general corporate purposes. 18-month exercise window. Upon full conversion, promoter holding rises from 48.87% to 53.52%—commitment to long-term value creation.
3 · Leadership: Deepal Shah appointed President – Strategy & Special Projects (Jul 31)
Chartered Accountant with 2+ decades experience. Timing suggests infrastructure for M&A integration and strategy execution post-capital raise. Routine organizational build-out.
4 · Auditor: Price Waterhouse appointed Statutory Auditor for 5 years (Jul 14)
Announced at 101st AGM. Transition from prior auditor; routine governance move. No audit qualification issues flagged.
5 · Deleveraging: JK Investors released share pledges (May 28)
Promoter group reduced encumbrance on shares—signal of reduced financial stress and improved balance sheet. Supportive for equity valuation.
RAYMOND is mid-pivot: a maturing textile conglomerate betting on defense, realty, and capital-efficient M&A to unlock next-phase growth. The Q1 FY27 print will be a first test of whether the strategic repositioning (new defense CEO, ₹331 Cr capital raise, leadership transitions) is translating into operational traction. Realistic expectations: 4–6% consolidated revenue growth on-plan, with margin pressure from one-time costs, partially offset by realty upside (129% pre-sales pop) and early defense momentum. The Street is watching but skeptical; analyst coverage is thin and consensus sits at Neutral/Hold.
Three things to watch on result day: (1) Textile segment margins—did domestic premiumization hold against garmenting order volatility post-tariff rally? (2) Realty pre-sales sustainability—was Q1 a one-off or a new baseline? (3) Defense operational milestones—has the new CEO identified near-term orders or partnerships to validate the ₹331 Cr M&A thesis? A credible story on (2) and (3) will shift the narrative from 'show-me' to 'multi-vector compounder.' Valuation (current ₹602 vs. consensus ₹625 target) leaves room for upside if execution delivers.
Strong aerospace growth masked by severe PAT collapse
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Aerospace guidance (25% growth) delivered/exceeded in Q1. But PAT collapse was not flagged as one-time; lack of transparency on bottom-line deterioration despite EBITDA growth.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong aerospace tailwinds (40% growth, ₹5.96 Tr order book, UK FTA/US tariff clarity) support long-term growth, but Q1 PAT collapse (99.4% YoY, NPM 4.9%) is unexplained and contradicts management's bullish tone. Execution risk is real; greenfield ramp and aftermarket launch are key 2H catalysts. Hold until PAT recovery is credibly demonstrated.
₹605.6 Cr
Revenue · +15.5% YoY₹30.9 Cr
Reported PAT · −99.4% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Total income ₹628 Cr, 13% YoY growth
MISSDelivered revenue ₹605.6 Cr, 15.5% YoY (₹22.4 Cr discrepancy vs call)
EBITDA ₹100 Cr, 14% YoY growth at 15.9% margin
OVERSTATEDImplies gross EBITDA; PAT only ₹30.9 Cr (NPM 4.9%, down from prior quarter)
Aerospace 40% revenue growth, 25% EBITDA growth
METSegment revenue ₹123 Cr, EBITDA ₹26 Cr (21.2% margin); R&D fully expensed (temporary margin compression)
Precision auto 11% revenue, 46% EBITDA growth on operating leverage
METSegment revenue ₹444 Cr, EBITDA ₹61 Cr (13.8% margin); export ramp-up and cost initiatives drove margin expansion
Net cash surplus ₹129 Cr (debt-free)
METStated as of June 2026; provides capex flexibility
Market demand far exceeds supply; execution is the constraint
METStrong RFQ pipeline (₹1,632 Cr) and order book (₹5,960 Cr 10-yr vs prior ₹2,350 Cr 5-yr) support claim
No meaningful supply chain risk exposure (unlike US aerospace supplier revisions)
OVERSTATEDCall later admits logistics costs, tool/carbide costs, minimum wage pressures; mitigation via efficiency and customer pass-through
Earnings quality
What changed since the last call
Order book horizon extended 5yr to 10yr
UpgradeAerospace order book ₹5,960 Cr (10-yr) vs prior ₹2,350 Cr (5-yr); reflects long-cycle aerospace business nature; 5-yr breakup ₹2,765 Cr (+17% QoQ)
Aerospace margin temporarily compressed
DowngradeQ1 FY27 EBITDA margin 21.2% vs prior 23.7% (Q1 FY26); R&D expenses written off to support 40% revenue growth. Management expects stabilization as new programs mature.
25% aerospace growth reaffirmed (outperformed)
NeutralGuidance maintained at 25% YoY (call: 'a good growth'); Q1 delivered 40% but management frames as execution excellence, not guidance raise. Tone: cautious, not promotional.
Aftermarket business strategy new
NewQ2 FY27 launch of automotive aftermarket product line to diversify revenue; leverages OEM-grade manufacturing and B2C heritage. Expected contribution unclear.
Capex plan and greenfield trajectory unchanged
Neutral₹1,000 Cr 5-yr capex (₹510 Cr aerospace, ₹430 Cr auto); Andhra Pradesh greenfield on track for late 2027 commercial production. No cost escalation disclosed.
The Q&A
Analysts pressed on RFQ-to-order conversion timing, customer concentration, M&A plans, and capex sufficiency. Management held firm on execution confidence and market opportunity, downplayed competition risk (22-year headstart, 25+ OEMs, high entry barriers). Acknowledged supply chain cost pressures but framed as manageable via efficiency. Q&A was moderately challenging; no harsh evasions but management deflected PAT questions by focusing on EBITDA and aerospace growth.
Capex funding and inorganic M&A — Yeshas Paramesh, Claridian
AnsweredCompany keeping options open across aerospace, auto, and defence. Warrants provide flexibility for opportunistic acquisitions. Will update market when definitive deals are close.
Supply chain bottlenecks — Yeshas Paramesh, Claridian
PartialNot yet exposed because critical-side castings/forgings not transferred to us. Supply chain constrained such that execution = competitive advantage. More backlog you clear, larger the backlog grows.
RFQ pipeline conversion — Nishita Shanklesha, Sapphire Capital
PartialDaily growth business. RFQs and product development happen daily. Choice of which orders to take (not constraint-limited). Goal is margin/ROCE fit and customer satisfaction, not order count maximization.
EBITDA margin trajectory — Nishita Shanklesha, Sapphire Capital
AnsweredYes, expect same trend as now at consolidated level; better than prior year. Will maintain momentum.
Aerospace segment growth and 25% guidance — Harshit Chheda, Centra Insights
AnsweredAerospace has higher growth rate than peers. Mgmt has committed 25% growth; we are 'a little bit ahead' in Q1 (40%), but 25% is a good growth commitment. Expect to keep momentum.
Value chain upgrade and certifications — Harshit Chheda, Centra Insights
AnsweredDefinite goal to upgrade value chain. Mix of critical components and subassemblies will keep increasing. Adding heat treatment, special processes at Andhra facility for vertical integration and OEM confidence.
New certifications — Harshit Chheda, Centra Insights
AnsweredJust received medical device certification today. Most aerospace certifications already in place. Have build-to-spec design certification now. New customers come with their own certification requirements.
Order book and 10-yr vs 5-yr horizon — Navin Vijay, NS Capital
AnsweredAerospace businesses are long-term in nature. 5-yr period is small; 10-yr gives longer visibility on potential. Changed horizon to reflect reality.
R&D capitalization vs expensing — Navin Vijay, NS Capital
AnsweredAll R&D is fully written off in same quarter. To achieve 40% growth, we accelerated new product development—all expensed. As products mature, efficiency and margins will normalize.
Asset turnover and ROCE targets — Vatsal Kothari, AlfAccurate
AnsweredAerospace: 1.8x–2.2x; Auto: 2.0x–2.5x. Target Aerospace EBITDA margin ~25% mature; Precision auto ~12%–13%. Balancing asset turns with margin expansion to maintain ROCE.
Customer concentration and diversification — Vatsal Kothari, AlfAccurate
Answered40%–45% with top 3 OEMs currently. Have 25+ global customers. Goal is to decentralize to 8–10 high-value customers over time. 40% concentration is quite diversified given limited customer pool in aerospace.
Order intake growth outlook — Vatsal Kothari, AlfAccurate
Answered25% growth is healthy organic growth in aerospace. Have enough orders to sustain that. Outperformed Q1, working towards that momentum. Commitment to market is 25% increase.
Engine criticality (N1-N4) mix — Vatsal Kothari, AlfAccurate
AnsweredNot in N1 yet (rotating parts). Predominant on engines (N2-N4). Asset turns decrease as you move up value chain; balancing mix to maintain ROCE. Safe to assume 50%–60% N4 now, rest N2–N3, goal to move higher over time.
Existing facility revenue potential — Niraj Mansingka, White Pine
AnsweredEarlier estimates ₹600 Cr, but we now believe we will exceed that. Parivartan improvement mandate bringing a lot of change. Expected to exceed ₹600 Cr now.
Greenfield approval timeline and ramp — Niraj Mansingka, White Pine
AnsweredUp to 6 months approval process. Look at FY28 for numbers to start, then slow ramp-up due to customer approvals. Precision auto starting in parallel. Making improvements to current facility to avoid slowdown.
Medical device certification upside — Keval Shah, Sanctum Wealth
DodgedToo early to share. Just received certification today. Will come back next quarter with plan. It's part of routine capability exploration; many such initiatives in progress.
Margin sustainability and inventory gains — Keval Shah, Sanctum Wealth
AnsweredExtremely sustainable. R&D pressure exists but will ease. Operating leverage from revenue growth is main driver; will continue as we grow. Product mix fluctuations possible but directionally stable.
Supply chain cost inflation — Keval Shah, Sanctum Wealth
AnsweredLogistics costs up, tool/carbide/HSS costs up, minimum wage pressures. Mitigating via efficiency, operating leverage, and customer discussions. May see some margin pressure quarters but will ease as solutions found.
Defence business expansion and BEL hire — Midhun James, Moat PMS
PartialBhanu Prakash Srivastava has joined. Working on Defence segment strategy. Will come back to market by next quarter or 2 with future plans.
Competition from Indian auto players entering aerospace — Midhun James, Moat PMS
AnsweredGood for us. 22-yr headstart, among first with engine parts; leader status. Demand so high, will take years to worry about competition. Collaborative industry due to few approved sources. China Plus One benefits all India. Aerospace is high-mix low-volume, not everyone can do it.
Adjacent opportunities and new verticals — Midhun James, Moat PMS
DodgedWill continuously explore adjacencies for margin/product expansion. As plans get concrete, will share on calls. Nothing to share right now.
Consolidated growth trajectory and aftermarket impact — Midhun James, Moat PMS
PartialNot committing numbers. Scenario much more positive. Combining Tools & Hardware with aftermarket creates synergies. Leveraging brand and existing markets. Aiming for better margin expansion, higher value products. Will take every step for right synergies.
Guidance
Aerospace: 25% YoY growth (reaffirmed, with 40% in Q1 outperformance)
HighPrior guidance maintained; Q1 delivery at 40% signals execution strength. Order book and RFQ pipeline sufficient to sustain momentum.
Consolidated: 12%–13% EBITDA margin range in FY27
MediumMgmt says expect same trend as Q1; better than prior year. However, product mix variability and cost inflation noted; not a ceiling.
Existing facility capacity: now expected to exceed ₹600 Cr (prior estimate)
MediumParivartan improvement initiative driving efficiency gains. No specific FY27 revenue guidance; baseline-to-FY28 may be more realistic given approval lags.
Aerospace: target 25% EBITDA margin at mature level
MediumQ1 at 21.2% due to R&D write-off (temporary). Management expects stabilization as new programs transition to steady-state production. Path credible but dependent on R&D payoff.
Precision auto: target 12%–13% EBITDA margin
HighQ1 achieved 13.8% on export mix uplift and cost initiatives. Operating leverage as volume grows will support. Product mix fluctuations expected quarter-to-quarter.
₹1,000 Cr over 5 years: ₹510 Cr aerospace, ₹430 Cr auto
HighOn track per management. Andhra Pradesh greenfield groundwork progressing; commercial production late 2027. Funded from internal accruals + net cash position.
Risks the call surfaced
PAT / profit quality
HighPAT fell 99.4% YoY to ₹30.9 Cr (NPM 4.9%) despite EBITDA +14% YoY. No one-time charge flagged on call. R&D expensing is ongoing, not one-time. Suggests Q1 FY26 had much higher PAT, or Q1 FY27 margin collapse is structural.
Supply chain & cost inflation
MediumLogistics costs up, tool/carbide/HSS inflation noted, minimum wage increases. Mitigation via efficiency and customer pass-through. Magnitude of cost inflation not quantified; timing unclear.
Greenfield execution and capacity timing
MediumAndhra Pradesh greenfield on track for late 2027 commercial production, but 6-month approval processes expected. FY28 is realistic ramp start, not FY27. If regulatory/customer approvals slip, capacity expansion delayed.
Customer concentration
MediumAerospace customer concentration at 40–45% for top 3 OEMs. While mgmt claims 25+ global customers, loss of a top OEM contract or design-win miss could materially impact growth. Diversification plan (move to 8–10 high-value customers) is aspirational, dependent on RFQ conversions.
Competitive intensity in aerospace
LowMany Indian auto component players now adding aerospace divisions to presentations. Management dismisses this risk (22-yr headstart, few approved sources, high-mix low-volume moat). However, China Plus One tailwind benefits all India; competitors may gain faster if OEMs diversify supply.
Management
Score 6/10. Clear on strategy and market opportunity; detailed on aerospace tailwinds, capex plan, and order book. Evasive on PAT collapse and medical/defence strategies (deferred to next quarter). Provides segment-level transparency but lacks candour on bottom-line deterioration. Aerospace 40% growth (beat 25% guidance) demonstrates strong execution. Precision auto 11% growth + 46% EBITDA growth supports operational leverage story. However, consolidated PAT down 99.4% YoY undermines credibility of execution track record; suggests either prior-year base issue or current-quarter margin shock not flagged.
1 · Q2 FY27
Automotive aftermarket product line commercial rollout; leverage OEM base & B2C brand
2 · H2 FY27 – FY28
Andhra Pradesh greenfield ramp (6 months approval lag); aerospace & auto capacity step-up
3 · Q2–Q3 FY27
RFQ-to-order conversion from ₹1,632 Cr pipeline; new defence mass production scaling
Hold until PAT recovery is credibly demonstrated.
Raymond Q1FY27: PAT +50% YoY (adj), Aerospace +40% beats guidance, margins expand
PAT -99.4% YoY · revenue +15.5% · margins expanding
₹605.61 Cr
+15.5% YoY
₹30.85 Cr
-99.4% YoY
4.91%
-95.1pp YoY
₹3.15
Raymond Limited's consolidated (primary) Q1 FY27 results show revenue from operations of ₹605.61 Cr (total income ₹628.10 Cr) and PAT of ₹30.85 Cr. On a reported basis PAT is down ~99% YoY, but that comparison is meaningless: the year-ago quarter's ₹5,328.15 Cr PAT included a ₹5,307.53 Cr one-off gain on the demerger of the Realty business, booked under discontinued operations. Stripping that out, continuing-operations PAT was ₹20.62 Cr in Q1 FY26, so the adjusted YoY PAT growth is ~+50%, on revenue growth of 15.5% YoY (605.61 vs 524.29) and 0.4% QoQ (605.61 vs 602.91). Standalone, now essentially a holding entity post the engineering-subsidiary restructuring, posted a token PAT of ₹1.69 Cr on ₹0.80 Cr of operating revenue — all the operating profit sits at the consolidated/subsidiary level.
Q1 FY-2027 vs prior quarters
Margins expanded on both cuts: group EBITDA of ₹100 Cr carried a 15.9% margin, up from 13.9% in Q4 FY26 and 15.7% a year ago. The expansion was driven almost entirely by Precision Technology & Auto Components, where EBITDA margin jumped to 13.8% from 10.6% YoY (EBITDA +45.5% to ₹61 Cr) on export volume growth, better product mix and operating leverage, even as revenue grew a more modest 11.5% to ₹444 Cr. Aerospace & Defence revenue rose 40.4% YoY to ₹123 Cr and EBITDA grew 25.4% to ₹26 Cr, but segment margin compressed to 21.2% from 23.7% — management attributes this to targeted R&D spend to capture the revenue ramp, and says margins will stabilize as programs reach steady state; that claim is unverified pending next quarter's print.
The stock went into the print at ₹614.95, down 0.9% over the past month of trading.
What the summary numbers don't show
Net cash surplus of ₹129 Cr as of June 2026 — company remains net-debt-free
Management guides for continued growth momentum, targeting 25% year-on-year growth in the Aerospace business, supported by a transformative INR 930 crore capex plan over five years. This investment, centered on a new greenfield facility in Andhra Pradesh, is designed to significantly scale capacity for surging internat
— This quarter: beat
Against the prior concall's guidance of 25% YoY growth in the Aerospace business, the actual 40.4% YoY growth is a clear beat, and the press release reiterates the ₹930 Cr Andhra Pradesh greenfield capex plan is "strictly on schedule." We found no specific street/consensus estimates published for this entity (distinct from the separately-listed Raymond Lifestyle and Raymond Realty, which did have previews) ahead of this print, so vsStreet is unknown. Management's own framing — a "healthy" quarter anchored by Aerospace/Defence and Precision Technology, per Chairman Gautam Hari Singhania — is consistent with the numbers: EBITDA and PAT both grew faster than revenue, evidencing operating leverage rather than just topline momentum. The quarter also saw two CEO/leadership appointments in the Aerospace vertical (Bhanu Prakash Srivastava as CEO-Defence, Deepal Shah as President-Strategy) and a new five-year statutory auditor (Price Waterhouse), alongside SEBI in-principle approval for a preferential warrant issue.
W1
Aerospace EBITDA margin trajectory — compressed to 21.2% from 23.7% YoY on R&D spend; management says it stabilizes as programs reach steady state, to be verified next quarter
W2
₹930 Cr Andhra Pradesh greenfield aerospace facility — press release says "strictly on schedule"; watch capex pace and capacity commentary in Q2 FY27
W3
Deployment of the ₹82.72 Cr upfront promoter warrant subscription and the balance 75% due within 18 months of the 7 July 2026 allotment
Aerospace Surges, Profit Collapses Unexplained—the Credibility Gap
The quarter delivered 40% aerospace growth and a ₹5,960 crore order book, but consolidated profit fell 99% YoY with no explanation. EBITDA grew 14%; profit imploded. Management didn't address the gap.
₹30.9 Cr
-99.4% YoY
+14% YoY
₹100 Cr at 15.9% margin
₹123 Cr
+40% YoY (beat 25% guidance)
₹5,960 Cr
Up from ₹2,350 Cr (5-yr)
Raymond delivered a tactically blowout aerospace quarter—40% growth, ₹5,960 crore order book, ₹1,632 crore live RFQ pipeline. The market bought it, posting a +1.96% rally on day 1 of the result announcement. But look deeper, and there's a credibility breach: consolidated PAT crashed 99.4% to ₹30.9 crore (NPM 4.9%), while EBITDA climbed 14%. That gap—where revenue and EBITDA grow but profit collapses—is the real quarter. And management didn't explain it.
The PAT-EBITDA divergence: where did ₹480 crore in profit go?
Revenue rose 15.5% YoY to ₹605.6 crore. EBITDA rose 14% (management: ₹100 crore at 15.9% margin). But net profit fell to ₹30.9 crore from an implied prior-year level of ~₹510 crore. The gap is ~₹480 crore—an 99% cliff. Management did not flag any one-time charge on the call. R&D is fully expensed to support 40% aerospace growth (management notes this will normalize as programs mature), but that is an ongoing operational cost, not a one-time item. The absence of an explanation for a 99% profit decline, despite EBITDA growth, is a material credibility risk. Either (1) prior year had an inflated profit that is now normalizing; (2) Q1 FY27 harbors unspoken cost shocks or customer mix deterioration; or (3) taxes, depreciation, or finance costs spiked. Until clarified, the order book story masks an earnings quality issue.
As these newly developed programs transition into steady-state production, EBITDA margins will stabilize.
Total income ₹628 Cr, 13% YoY growth
Delivered ₹605.6 Cr, 15.5% YoY (₹22.4 Cr discrepancy vs call)
Contradicted
Aerospace 40% growth, 25% EBITDA growth
Aerospace ₹123 Cr (+40%), EBITDA ₹26 Cr (21.2% margin, down from 23.7% YoY; R&D fully expensed)
Supported (growth yes; margin compression material)
Precision auto 46% EBITDA growth on operating leverage
Precision auto ₹444 Cr (+11%), EBITDA ₹61 Cr (13.8% margin, up from 10.6%). Export ramp-up confirmed.
Supported
No meaningful supply chain risk exposure
Q&A later admits logistics, tool/carbide, wage cost inflation. Mitigation via efficiency and customer pass-through not quantified.
Overstated
Market demand far exceeds supply; execution is the constraint
RFQ pipeline ₹1,632 Cr and 10-yr order book ₹5,960 Cr support this. But RFQ-to-order conversion timing and customer diversification (40–45% top 3) unproven.
Supported (with execution caveat)
Margins will stabilize and improve
Aerospace EBITDA margin fell from 23.7% to 21.2% YoY. Cost headwinds ongoing; pricing power effectiveness unproven.
Aspirational, not guaranteed
What changed on this call
Order book horizon extended from 5-year to 10-year (₹5,960 Cr vs prior ₹2,350 Cr 5-yr)
Aerospace margin temporarily compressed to 21.2% due to R&D acceleration; normalization timing not specified
Aftermarket automotive product line launching Q2 FY27 (new revenue lever; contribution size unknown)
Defence segment strategy in development (ex-BEL CXO hired); color deferred to next quarter
Medical device certification just received (new vertical; pipeline unknown; color deferred)
Capex plan (₹1,000 Cr, ₹510 Cr aerospace, ₹430 Cr auto) and greenfield timeline (late 2027) reaffirmed
How the street is positioned
The stock rallied +1.96% on day 1 of the result (from ₹614.95 pre-announcement close), with 39.9% delivery volume; by day 3, the pop had moderated to +0.65%. The market chose to buy the aerospace narrative (40% growth, extended order book, UK FTA tailwind) and overlook the PAT collapse. Classic sell-the-profit-miss-buy-the-order-book optics. Yet institutional positioning reveals caution: FII ownership fell 1.86 percentage points QoQ (from 9.75% to 7.89%), a sell-on-good-news signal despite bullish call tone. The stock is trading at ₹642 as of mid-August, just 0.53% below its all-time high of ₹645.4. All key moving averages (SMA20 ₹606.96, SMA50 ₹595.03, SMA200 ₹480.5) are below the current price; RSI is at 67.7 (neutral, not yet overbought). Risk/reward is skewed to the downside—the stock has rallied 100% off its 52-week low (₹320.55) and sits at the ceiling of its range. There is no margin of safety for a holder concerned about profit credibility.
The bull-bear ledger
Aerospace in a structural up-cycle; global OEM build rates stabilizing at higher target production
10-year order book ₹5,960 Cr and RFQ pipeline ₹1,632 Cr provide concrete decade-long revenue runway
UK-India FTA and US tariff clarity are multiyear tailwinds; China Plus One reallocation benefits all Indian suppliers
22-year aerospace headstart, build-to-spec design certification, 25+ OEMs, and approved-source moat create formidable barriers to entry
Precision auto segment executing: +11% revenue, +46% EBITDA growth from export ramp and operating leverage
Net cash ₹129 Cr and zero debt provide capex flexibility for ₹1,000 Cr greenfield plan
PAT crashed 99% YoY with zero explanation on call; breach of earnings credibility and transparency
Aerospace EBITDA margin fell to 21.2% from 23.7% YoY; cost headwinds (logistics, tools, wages) unquantified and pricing mitigation informal
Greenfield approval lag (6 months) shifts upside to FY28; existing facility ceiling ₹600 Cr limits near-term growth
Customer concentration 40–45% with top 3 OEMs; diversification to 8–10 customers is aspirational, execution-dependent
FII trimmed 1.86pp despite bullish aerospace optics; institutional skepticism on profit quality
Stock at all-time high with no margin of safety; price above all key moving averages limits upside room
Risks, ranked by what should concern a holder
PAT credibility and earnings quality
HighProfit fell 99% YoY while EBITDA grew 14%. If structural (customer mix deterioration, cost shock, prior-year base reset), 25% aerospace growth will not translate to shareholder returns. If one-time, Q2 recovery is critical. Lack of management transparency is a red flag.
Cost inflation mitigation unproven
HighLogistics, tool/carbide, HSS, and wage costs are up. Management claims efficiency and customer pass-through, but magnitude and timeline unspecified. If price realization lags, margin targets (Aerospace 25%, Precision auto 12–13%) are at risk.
Greenfield execution and approval lag
MediumCommercial production late 2027 with 6-month approval lag. FY28 is the realistic ramp start. Current facility ceiling ~₹600 Cr limits organic growth until then. Regulatory delays could push upside further out.
Customer concentration and RFQ conversion
MediumTop 3 OEMs represent 40–45% of order book. Diversification depends on ₹1,632 Cr RFQ-to-order conversion. If win rates slip or new customer ramp stalls, concentration risk persists and customer loss becomes more material.
Institutional positioning deteriorating
MediumFII trimmed 1.86pp QoQ (from 9.75% to 7.89%) despite bullish call optics. Sell-on-good-news signal suggests institutional doubt. If FII selling accelerates, price support weakens.
Valuation at all-time high with limited margin of safety
MediumStock at ₹642, 0.53% below ATH ₹645.4, up 100% off 52-week low. A disappointment on Q2 PAT or margin guidance could trigger sharp correction.
The debate
1 · Q2 FY27 PAT recovery (most critical metric)
If NPM rebounds to 8–9% and PAT exceeds ₹50 Cr, Q1 collapse was one-time and credibility recovers. If PAT stays at 4.9% or worsens, something is structurally broken. This single metric will determine whether the aerospace growth story translates to shareholder returns.
2 · Cost inflation quantification and pricing power evidence
Management must disclose magnitude of logistics/tool/wage pressures and show Q2 gross or EBITDA margin trends that prove efficiency + price pass-through are working. This determines path to target margins (Aerospace 25%, Precision auto 12–13%).
3 · Greenfield approval milestones and RFQ-to-order conversion
Track regulatory/customer approvals for Andhra Pradesh facility; delays signal execution risk. Monitor ₹1,632 Cr pipeline conversion rates and new customer wins—proof of diversification from top-3 OEM concentration (currently 40–45%).
4 · Aftermarket rollout traction and defence strategy reveal
Q2 aftermarket launch contribution and Q2–Q3 defence segment strategy detail are upside catalysts if credible. Size these relative to aerospace/auto to assess diversification upside.
Raymond delivered a tactically strong quarter on aerospace (40% growth, ₹5,960 Cr order book) but a strategically weak one on profit credibility. The market rewarded the narrative (+1.96% day 1) and absorbed the order book story. But the 99% PAT collapse, unexplained on the call and unaddressed in management commentary, is the real earnings story. Until management reconciles that gap—either by proving Q1 is one-time or transparently explaining structural margin compression—the bull case remains a story about volumes, not profits.
For a holder, the single number to track is Q2 PAT. If it rebounds to a reasonable NPM (8–9%), the aerospace thesis holds and the stock can justify near-ATH valuations with cautious confidence. If PAT stays depressed, the order book and capex become footnotes in a profit-quality miss, and the stock deserves a lower multiple.
Verdict: Hold. Aerospace tailwinds are real and multiyear, but execution risk is high and valuation is at the peak of the range. Accumulate on any correction below ₹600; hold existing positions above ₹600 until Q2 PAT clarifies the profit-quality debate.